| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 47.3MM | -5% |
| Gross Profit | 37MM | - |
| Cost Of Revenue | 10.3MM | +8% |
| Operating Income | 2.3MM | -58% |
| Operating Expenses | 34.7MM | - |
| Net Income | 1.2MM | -66% |
| G&A | 13MM | +2% |
| Marketing | 21.7MM | -2% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
There are some industrial stocks that short sellers are targeting heavily in April this year. Short sellers often target stocks they perceive to be overvalued or companies facing significant challenges or headwinds. By short selling, they stand to profit if the stock price drops as they can buy back the borrowed shares at a lower cost than what they sold them for initially. Thus, a high short interest can be both a warning sign and an opportunity, depending if you own or want to sell shares. The
Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it is a recipient of the prestigious 2024 Top Workplaces USA award, featured in USA TODAY. This achievement underscores the organization's dedication to fostering a people-first workplace culture and prioritizing the employee experience.
Key Insights Zynex's significant insider ownership suggests inherent interests in company's expansion The top 2...
Zynex ( NASDAQ:ZYXI ) Full Year 2023 Results Key Financial Results Revenue: US$184.3m (up 17% from FY 2022). Net...
Zynex, Inc. (NASDAQ:ZYXI) Q4 2023 Earnings Call Transcript February 29, 2024 Zynex, Inc. beats earnings expectations. Reported EPS is $0.21, expectations were $0.17. ZYXI isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen. And welcome to […]
By Exec Edge Editorial Staff RBC Capital analyst Shagun Singh maintained Zynex, Inc. (Nasdaq:ZYXI) with an outperform rating and raised its price target from $13 to $15. Meanwhile, HC Wainwright & Co. analyst Yi Chen maintained a buy rating and raised its price target from $20 to $21. The Englewood, CO. company, founded in 1996, […]
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -76.47% and 12.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Despite Revenue Uplift, Net Income and Adjusted EBITDA Experience Downturn
Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2023 and its Board of Directors has approved an additional program to repurchase up to $20.0 million of the Company's common stock.
Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, February 29, 2024 at 4:15 PM Eastern Time to discuss its financial results for the fourth quarter and full year ended December 31, 2023. Financial results will be issued in a press release prior to the call.